Skip to main content
Black Health logo Black Health
Policy

HHS launched the MAHA Action Plan to curb psychiatric overprescribing on May 4. The Black-mental-health pattern is under-treatment, not over-treatment.

Updated 8 min read

Editorial review

Reviewed by the Black Health editorial team against our editorial standards. Last updated . How we source.

Diagram: four cards on the May 2026 federal prescribing plan: what it targets, evidence that the gap is under-treatment, what to ask if a taper comes up, and asking for an exception if coverage is denied.
Illustration: Black Health
Six US peer-reviewed studies covering adult depression, pediatric ADHD, Medicare dementia, and Medicaid pediatric antipsychotic care document the consistent direction: Black patients receive psychiatric medications at lower rates than white peers, even when diagnosis is established. A blanket federal effort to reduce psychiatric prescribing, applied without race-stratified safeguards, risks compounding the existing under-treatment pattern documented across all six.
On this page

On May 4, 2026, the US Department of Health and Human Services announced the Make America Healthy Again Action Plan to Curb Psychiatric Overprescribing, a multi-agency federal effort targeting antidepressants, antipsychotics, and stimulants with a child-focused emphasis (HHS news release, May 4, 2026, as reported by Psychiatric Times on May 5, 2026). The analysis below rests on peer-reviewed evidence about who actually receives psychiatric medications in the US, not on the announcement's framing. Named priorities the announcement carries include provider education, informed consent, shared decision-making, tapering and discontinuation, and nonmedication approaches.

The peer-reviewed US literature on who receives psychiatric medications runs in the direction the Action Plan does not name. A 2011 analysis of the National Comorbidity Survey-Replication found that among US adults with a 12-month major depressive disorder diagnosis, Black respondents reported antidepressant use at 17.5 percent and white respondents at 37.6 percent (Fleming et al., Journal of the American Pharmacists Association 2011; PMID 21896458). The Black-vs-white antidepressant-use gap, in the population with diagnosed depression, is under-treatment by a factor of roughly two.

What seven US studies document

The Fleming team's NCS-R analysis is one of six US peer-reviewed studies below that show the same pattern across drug classes and care settings. A seventh, on risky medicines in older adults, shows something different.

A 2013 analysis of Florida Medicaid pediatric ADHD claims covering fiscal years 1996 through 2005 found that Black children and adolescents diagnosed with ADHD had lower ADHD-medication utilization than white peers across every year studied (Saloner et al., Journal of Child and Adolescent Psychopharmacology 2013; PMID 23952187). The introduction of long-acting stimulant formulations during the study window did not close the utilization gap.

A 2015 analysis of 5.8 million Medicaid-enrolled children ages 2 to 20 across eight US states covering 2005 through 2009 found that, with other factors held constant, Black children's probability of an antipsychotic fill was 1.8 percentage points lower than white children's. Only 2.4 percent of child-years in the study had any antipsychotic fill, which is why the authors call that gap large (Cataife and Weinberg, Psychiatric Services 2015; PMID 25975884). A 2023 national trend analysis of Medicaid-insured children ages 2 to 17 from 2008 to 2016 found declines in antipsychotic prescribing across all racial and ethnic groups studied, with the under-treatment direction for Black children persisting through the 2008 to 2016 window (Bushnell et al., Health Affairs 2023; PMID 37406239).

A 2024 analysis of 2017 through 2019 Medicare fee-for-service data on persons living with dementia found that Black PLWD were 11.7 percentage points less likely than white peers to be diagnosed with the behavioral and psychological symptoms of dementia (56.6 percent vs 68.3 percent), and 8.5 percentage points less likely to receive a central-nervous-system-active drug conditional on diagnosis (70.8 percent vs 79.3 percent) (Thunell et al., Journal of Alzheimer's Disease 2024; PMID 38669535). A 2025 JAMA Network Open analysis of 21,193,170 Medicare beneficiaries across Part D, fee-for-service, and Medicare Advantage covering 2016 through 2019 found that Black beneficiaries used high-risk medications less often than white beneficiaries (12.6 percent vs 14.2 percent) (Raver et al., JAMA Network Open 2025; PMID 40227682). High-risk here means potentially inappropriate medicines, whose risks outweigh their benefits for older adults, so that gap is not under-treatment; the authors call for fewer such prescriptions in every group. A 2025 Health Affairs Scholar analysis covering community-dwelling Medicare older adults with dementia 2010 through 2018 found that minority-combined antipsychotic prescribing in 2016 to 2018 was 13.8 percent vs white 17.5 percent, with the under-treatment direction persisting across all three Choosing Wisely time periods (Yang et al., Health Affairs Scholar 2025; PMID 40040648).

Six of these seven studies point one way, across four drug classes and more than two decades of data: under-treatment in the Black population, even when diagnosis is established.

The policy-impact squeeze

A blanket federal effort to reduce psychiatric prescribing, applied without race-stratified safeguards, runs into the population evidence above in a specific way. The provider-education and tapering mechanisms named in the MAHA Action Plan target a population the policy assumes is over-prescribed. The six treatment studies above describe a Black-patient population that is under-prescribed across antidepressants, stimulants, antipsychotics, and CNS-active drugs in dementia. Applying a uniform reduction-in-overprescribing policy to a non-uniform prescribing baseline produces an asymmetric squeeze.

For Black children specifically, the Saloner 2013, Cataife 2015, and Bushnell 2023 findings describe a pediatric Medicaid prescribing baseline that is already low and trending lower across both stimulants and antipsychotics. A child-focused MAHA priority that adds further prescribing-reduction pressure on top of this baseline operates against a population whose access was already constrained.

For Black older adults with dementia, the Thunell 2024 11.7-percentage-point lower BPSD diagnosis rate is the upstream constraint. A clinician who does not document BPSD in a Black patient's chart cannot prescribe an FDA-approved on-label treatment for it. Our coverage of the FDA's April 30, 2026 approval of Auvelity for Alzheimer's-related agitation walks through this gate-then-prescription chain in detail.

The pattern fits what has shown up in two other recent health-policy decisions. The FDA's Auvelity approval did not include race-stratified efficacy and safety data from its two larger registration-supportive trials. The American Cancer Society's 2023 lung-cancer-screening guideline update, a professional-society guideline rather than federal policy, widened the Black-vs-white eligibility disparity for former smokers who developed lung cancer from 7 percentage points to 12 percentage points (Manful et al., Chest 2026; PMID 41580073; our coverage). MAHA is a third recent policy frame applied without race-stratified design to a population the evidence describes as differently treated, not over-treated.

What the policy does not yet name

Three things the May 4, 2026 announcement, as reported, does not pin down. It sets no published reduction targets or metrics by drug class. It names no race-stratified safeguards or equity provisions. And state-level implementation, including any prior-authorization changes, will likely determine which populations bear the downstream squeeze.

Community mental health centers see patients on a sliding scale, and they take patients a private practice would turn away over insurance. If you're in crisis right now, our crisis resources page lists free, immediate options. Our directory of free and charitable clinics lists centers by state. A paid online mental health platform is not billed to Medicaid, so check the community mental health center in your county first. If you want to start with a paid platform today:

BetterHelp

Talk to a licensed therapist online.

20% off your first month

Get started, 20% off

Compare every online therapy option we review →

Five named voices on the evidence and policy layers

The published evidence base is anchored by Marc Fleming, PhD, RPh, of the University of Texas at Austin College of Pharmacy (lead author Fleming 2011 NCS-R analysis); Brendan Saloner, PhD, of the Johns Hopkins Bloomberg School of Public Health Department of Health Policy and Management (lead author Saloner 2013 Florida Medicaid ADHD analysis; at Penn Robert Wood Johnson Scholars Program at time of original publication); Guido Cataife, PhD, of IMPAQ International (lead author Cataife 2015 8-state Medicaid pediatric antipsychotic analysis); Greta Bushnell, PhD, of Rutgers University (lead author Bushnell 2023 national Medicaid pediatric antipsychotic-trend analysis); and Mark Olfson, MD, MPH, of Columbia University Vagelos College of Physicians and Surgeons and the New York State Psychiatric Institute (senior author on the Bushnell 2023 analysis and the canonical US voice on psychiatric-prescribing trends).

The Black-mental-health-policy voice is Rahn Bailey, MD, FAPA, ACP, current president of the Black Psychiatrists of America and concurrently American Psychiatric Association President-Elect; the dual role makes him uniquely positioned to speak for both the Black-psychiatry constituency and the incoming APA leadership perspective on the Black-mental-health implications of the Action Plan.

Three things to do, depending on who you are

For Black adults or caregivers of Black children currently on a psychiatric medication. If your prescriber raises tapering, discontinuation, or dose reduction as a response to the new federal framework, ask for the clinical rationale in your specific case, separate from the policy framing. The Action Plan named tapering and discontinuation as priorities; clinically appropriate tapering is the standard of care for many medication-and-symptom combinations, but a policy-driven taper applied without your clinical specifics is a different conversation. Ask the prescriber to document the rationale in the chart.

For Black parents of children diagnosed with ADHD, depression, or another condition for which stimulants, antidepressants, or antipsychotics are part of the care plan. Document the diagnostic basis for any current prescription and ask the prescriber what the under-prescribing-in-Black-Medicaid-pediatric-populations finding from peer-reviewed studies (Saloner 2013, Cataife 2015, Bushnell 2023) means for your child's specific care. A prior-authorization denial or formulary-tier change citing the MAHA framework is a moment to ask for an exception based on the documented diagnostic and treatment record.

For Black mental-health-policy advocates and Black-led mental-health organizations. The Black Psychiatrists of America operates at blackpsychiatrists.org and is the institutional anchor for Black-psychiatry policy positions. The American Psychiatric Association's Caucus of Black Psychiatrists is the larger-APA structural counterpart. State-level implementation comments on prior-authorization changes for the affected drug classes are likely the primary policy lever in the coming 12 months. The Black Health provider directory lists Black psychiatrists, psychologists, and primary-care clinicians for readers who want a clinician engaged with the under-treatment-vs-over-treatment evidence base.

What we will add

We will update this piece if HHS publishes reduction targets or safeguards, when state-level prior-authorization data emerges, or when peer-reviewed, race-stratified prescribing data from after the plan is published.

Citations

HHS Press Room. HHS Launches MAHA Action Plan to Curb Psychiatric Overprescribing. May 4, 2026. https://www.hhs.gov/press-room/hhs-launches-maha-action-plan-curb-psychiatric-overprescribing.html

Psychiatric Times. HHS Launches Action Plan to Promote "Appropriate Psychiatric Prescribing." May 5, 2026. https://www.psychiatrictimes.com/view/hhs-launches-action-plan-to-promote-appropriate-psychiatric-prescribing

Fleming M, Barner JC, Brown CM, Smith T. Treatment disparities for major depressive disorder: Implications for pharmacists. Journal of the American Pharmacists Association. 2011;51(5):620-624. PMID 21896458.

Saloner B, Fullerton C, McGuire T. The impact of long-acting medications on attention-deficit/hyperactivity disorder treatment disparities. Journal of Child and Adolescent Psychopharmacology. 2013;23(6):401-409. PMID 23952187.

Cataife G, Weinberg DA. Racial and Ethnic Differences in Antipsychotic Medication Use Among Children Enrolled in Medicaid. Psychiatric Services. 2015;66(9):946-953. PMID 25975884.

Bushnell GA, Lloyd J, Olfson M, Cook S, Das H. Antipsychotic Medication Use In Medicaid-Insured Children Decreased Substantially Between 2008 And 2016. Health Affairs. 2023;42(7):973-980. PMID 37406239.

Thunell JA, Joyce GF, Ferido PM, Chen Y, Guadamuz JS, Qato DM, Zissimopoulos JM. Diagnoses and Treatment of Behavioral and Psychological Symptoms of Dementia Among Racially and Ethnically Diverse Persons Living with Dementia. Journal of Alzheimer's Disease. 2024. PMID 38669535.

Yang AW, Leng M, Arbanas JC, Tseng CH, Fendrick AM, Sarkisian C, Damberg CL, Harawa NT, Mafi JN. Trends in antipsychotic prescribing among community-dwelling older adults with dementia, 2010-2018. Health Affairs Scholar. 2025. PMID 40040648.

Raver E, Jung J, Carlin C, Feldman R, Retchin S, Xu W. Racial and Ethnic Differences in Potentially Inappropriate Medication Use Among Medicare Beneficiaries. JAMA Network Open. 2025. PMID 40227682.

Manful A, Amanna N, Park SL, Petrick JL, Rosenberg L, Tindle H, Palmer J, Wilkens L, et al. The Impact of the 2023 American Cancer Society Screening Recommendations on Racial, Ethnic, and Sex Disparities in Lung Cancer Screening Eligibility. Chest. 2026. PMID 41580073.

Corrections

  • : Editors' notes and a missing resource. What we changed
  • : Studies on psychiatric prescribing for Black patients. What we changed
  • : Editing notes published as article text. What we changed

Read next

SNAP Work Rules 2026: Who Must Work and Who Is Exempt

Since July 4, 2025, SNAP's time limit covers adults ages 18 to 64 unless they have a child under 14 in their SNAP household or meet another exception. If it applies, you get 3 months of SNAP in 3 years unless you work, train or volunteer 80 hours a month. Veterans and people experiencing homelessness lost their exceptions. If you get a notice, ask for a fair hearing.

Continue reading

Medical Disclaimer

This content is for informational and educational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition.

Newsletter

One email a week with essential Black health guidance, plus a featured provider.

No spam. Unsubscribe anytime.

Was this helpful?

Your feedback shapes what we cover next.

Thanks for letting us know.

If you found this useful, sign up for our newsletter to get more like this.

Thanks. What was missing?

Optional. We read every response.

Thanks.

We use this to prioritize the next round of edits.

Follow Black Health for more

More from Zuri Carter

More in Policy